EC 09 - 1:1 ASTRO Patient Education on Epic MyChart Care Companion III
● Special Session
In Person Only
📍 Northeast Lobby B and Room 155 - Early Career and Mentoring Lounge
Interested in bringing ASTRO's radiation oncology care plans into Epic MyChart Care Companion? Stop by the Early Career Lounge for one-on-one conversations with Epic representatives about the ASTRO-Epic collaboration.Interested in bringing ASTRO's radiation oncology care plans into Epic MyChart Care Companion? Stop by the Early Career Lounge for one-on-one conversations with Epic representatives about the ASTRO-Epic collaboration.
Epic experts will be available to discuss how the care plans work within MyChart Care Companion, answer your questions, and provide practical guidance on implementation and setup at your institution. Whether you're exploring the program, preparing for deployment, or looking to optimize your current use, this is an excellent opportunity to get personalized advice and learn from the experts.
No formal presentation, just drop in and connect with the team behind this innovative collaboration aimed at enhancing the patient experience throughout radiation therapy.
This event is in-person only and will not be livestreamed or available onDemand.read more · Original Link ↗
Scott Gottlieb, MD, is a physician and served as the 23rd Commissioner of the U.S. Food and Drug Administration.Scott Gottlieb, MD, is a physician and served as the 23rd Commissioner of the U.S. Food and Drug Administration. He is currently a senior fellow at the American Enterprise Institute for Public Policy Research and a partner at the venture capital firm New Enterprise Associates.
Under Dr. Gottlieb's leadership, the FDA advanced new frameworks for the modern oversight of gene therapies, cell-based medicines, and digital health devices. He promoted policies to reduce death and disease from tobacco, improve food safety, and aggressively confront addiction crises. The agency's prolific advances in new policy distinguished his tenure as FDA Commissioner, along with a record-setting number of approvals for novel drugs, medical devices, and generic medicines.
Dr. Gottlieb is the author of the New York Times bestselling book Uncontrolled Spread: Why Covid-19 Crushed Us and How We Can Defeat the Next Pandemic and is a regular contributor to CNBC and CBS News' Face the Nation. In 2018 and again in 2019, Dr. Gottlieb was recognized by Fortune Magazine as one of "The World's 50 Greatest Leaders" and by Time Magazine as one of the "50 People Transforming Healthcare." Dr. Gottlieb is an elected member of the National Academy of Medicine and completed medical school and a residency in internal medicine at the Mount Sinai School of Medicine. He graduated from Wesleyan University, where he majored in economics, and currently serves on the university's board of directors. Dr. Gottlieb lives in Connecticut with his wife and three daughters.
Learning Objectives:
- Discuss role of Radiation Oncology in the general schema of health care
- Assess how the profession of Radiation Oncology can advance patient careread more · Original Link ↗
Celebrate the individuals who define excellence in radiation oncology at the ASTRO Annual Meeting Awards Ceremony - a meaningful and inspiring start to your day.Celebrate the individuals who define excellence in radiation oncology at the ASTRO Annual Meeting Awards Ceremony - a meaningful and inspiring start to your day. This distinguished gathering begins with the presentation of our Mentorship Awards, honoring individuals whose dedication to guiding and supporting the next generation has made a lasting impact across careers and institutions. We then recognize our newest Honorary Member, celebrating exceptional global leadership and meaningful contributions to the field. The ceremony continues with the formal induction of the 2026 Class of ASTRO Fellows, recognizing members for their sustained service, leadership and commitment to both ASTRO and the radiation oncology community.
The ceremony culminates with the presentation of the ASTRO Gold Medal, the Society's highest honor, awarded to an individual whose extraordinary lifetime achievements have shaped the specialty and advanced patient care worldwide.
Join colleagues and friends for this signature event - an uplifting celebration of mentorship, leadership and the people who move our profession forward.
Learning Objectives:
- NA
- NAread more · Original Link ↗
CL 03 - A Dose of Art: The Art, Poetry, and Humanity of The Red Journal and Radiation Oncology
● Special Session
In Person Only
📍 Northwest Lobby B1 - ASTRO Communities Lounge
This session explores how the arts and humanities can enrich radiation oncology practice, education, and wellbeing.This session explores how the arts and humanities can enrich radiation oncology practice, education, and wellbeing. Speakers will highlight the role of art and poetry in The Red Journal, share physician-artist perspectives, and offer practical ways to use the arts to strengthen observation, empathy, reflection, and resilience in clinical care.
This event is in-person only and will not be livestreamed or available onDemand.read more · Original Link ↗
Matthew Farrell, MD, MFAModerator - UCLA Radiation Oncology
Take a session break in the Paw Zone and enjoy some cuddle time with our lovable canine companions. Your perfect pick-me-up is just a wag away!Take a session break in the Paw Zone and enjoy some cuddle time with our lovable canine companions. Your perfect pick-me-up is just a wag away! Studies have shown that petting a dog lowers stress and anxiety and has lasting mental health benefits.
This event is in-person only and will not be livestreamed or available onDemand.read more · Original Link ↗
Angela Carmona (Senior Publisher, Elsevier) will be available to discuss publishing and any questions you may have during ASTRO's Annual Meeting.Angela Carmona (Senior Publisher, Elsevier) will be available to discuss publishing and any questions you may have during ASTRO's Annual Meeting. Some topics could include tools and resources for authors, editors, and reviewers; how the peer review and publication process work; publishing open access; understanding ethics and best practices; and more.
This event is in-person only and will not be livestreamed or available onDemand.read more · Original Link ↗
☆
Tue Sep 29 · 12:30 PM - 1:30 PM
QP 20 - Beyond Treatment: Innovations in Supportive Care Across the Radiation Oncology Continuum
● Quick Pitch
📍 Room 109
Quick Pitch sessions provide opportunities for presenters to summarize outcomes while highlighting key takeaways from their research in a fast-paced format to present concise takeaways. · Original Link ↗
Molly Tate, PhD, MSN, APRN, FNP-CModerator - MD Anderson Cancer Center
Lizbet Flores, MSN, RN, ROCNModerator - AIS Cancer Center - Adventist Health Bakersfield
☆
Tue Sep 29 · 12:30 PM - 1:30 PM
QP 19 - Research to Inform Healthcare Access Interventions in Radiation Oncology
● Quick Pitch
📍 Room 259
Quick Pitch sessions provide opportunities for presenters to summarize outcomes while highlighting key takeaways from their research in a fast-paced format to present concise takeaways. · Original Link ↗
Janna Andrews, MD, FASTROModerator - North Shore-Long Island Jewish Health System
Luca Valle, MDModerator - UCLA Radiation Oncology
☆
Tue Sep 29 · 12:30 PM - 1:45 PM
EDU 37 - ASTRO GI Guideline Session: Radiation Therapy for Gastric Cancer and Pancreatic Cancer: A Case-Based Interactive Discussion
● Education
📍 Room 162
This is a case-based session designed to provide attendees with practical guidance on two new ASTRO gastrointestinal (GI) guidelines. The session will highlight key recommendations and guidance based on new evidence from the gastric cancer and pancreatic cancer guidelines.This is a case-based session designed to provide attendees with practical guidance on two new ASTRO gastrointestinal (GI) guidelines. The session will highlight key recommendations and guidance based on new evidence from the gastric cancer and pancreatic cancer guidelines.
Gastric - Gastric cancer is the fifth most common malignancy globally and fifth in mortality with significant geographic variability. The treatment of gastric cancer is complex and multidisciplinary, employing surgery, systemic therapy and RT. Although other investigators and clinical societies have published guidelines for gastric cancer, there is a need for expert-based guidance on interpreting contemporary literature. This session will provide an in-depth overview clarifying the role of RT in the management of all stages of gastric cancer.
Pancreas - Pancreatic cancer is projected to be the second leading cause of cancer-related mortality by 2030. Since publication of ASTRO's 2019 guideline, multiple randomized controlled trials have been published that have significantly influenced the standard of care for RT in the management of pancreatic cancer. In addition, RT techniques have evolved significantly since the publication of the prior ASTRO guidelines related to both dose and target volume escalation, facilitated by online adaptive RT and improved image guidance especially with MRI. These technical advances have led to promising outcomes and potentially new indications for RT in pancreatic cancer management. We plan to present updated pancreatic cancer guidelines that reflect these important changes since the publication of the prior ASTRO guidelines.
Learning Objectives:
- Identify appropriate clinical indications for RT in pancreatic and gastric cancer management.
- Determine optimal RT dose and technique for pancreatic and gastric cancer.
- Implement optimal systemic therapy regimens with or without RT for resectable, non-metastatic locoregionally advanced gastric cancer patients.read more · Original Link ↗
Christopher Willett, MD, FASTROModerator - Duke University Medical Center
Daniel Chang, MD, FASTROModerator - University of Michigan
☆
Tue Sep 29 · 12:30 PM - 1:45 PM
SS 42 - Advanced Lung Cancer and Drug Combinations
Praveen Pendyala, MDModerator - Cleveland Clinic Taussig Cancer Center
Michelle Alonso-Basanta, MD, PhD, FASTROModerator - University of Pennsylvania
☆
Tue Sep 29 · 12:30 PM - 1:45 PM
EDU 38 - At the Margins: Navigating Challenging Vulvar and Vaginal Cancers
● Education
📍 Room 257
This case-based session will explore emerging treatment paradigms for the management of vulvar and vaginal cancer.This case-based session will explore emerging treatment paradigms for the management of vulvar and vaginal cancer. Although relatively rare, the incidence of vulvar and vaginal cancers is rising, and our understanding of how to best treat these diseases has evolved with the recent publication of studies such as GROINSS V-II, GOG 279, and RetroEMBRAVE. There is also increased awareness of the molecular drivers which may impact prognosis and influence treatment approaches. Session speakers will address the latest data regarding the management of node positive and locally advanced vulvar cancer including the appropriate incorporation of sentinel node biopsy, standardized contouring guidelines and treatment techniques for IMRT, and when to consider brachytherapy boost to gross primary disease. Similarly for vaginal cancer, participants will become familiar with the recently published GEC-ESTRO contouring recommendations, and the data driving the increased use of image-guided brachytherapy and the potential benefit of escalating doses for T2-T4 tumors.
Learning Objectives:
- Recognize settings in which sentinel node biopsy versus lymph node dissection should be used in node positive vulvar cancer.
- Distinguish when locally advanced vulvar patients should be managed with neoadjuvant versus a definitive radiation approach +/- brachytherapy boost.
- Implement standardized treatment volumes and image-guided brachytherapy for vaginal cancers.read more · Original Link ↗
Dominique Rash, MDModerator - UCSD Health
☆
Tue Sep 29 · 12:30 PM - 1:45 PM
International 04 - Challenges and Solutions of Implementing New Radiotherapy Advanced Techniques in LMICs
● Education
📍 Room 253
This session will share institutional experiences highlighting successful implementation of advanced radiotherapy techniques in low- and middle-income countries (LMICs).This session will share institutional experiences highlighting successful implementation of advanced radiotherapy techniques in low- and middle-income countries (LMICs). Despite significant disparities in access to radiotherapy and technological resources, many centers in resource-constrained settings have developed innovative, scalable and context-adapted solutions that allow the safe and effective delivery of modern radiation treatments.
The session will describe the development of real-world institutional projects, outlining the clinical, technical, organizational and financial challenges encountered during implementation. Key barriers such as limited infrastructure, workforce shortages, training gaps, regulatory constraints and sustainability concerns will be discussed. Emphasis will be placed on the strategies used to overcome these obstacles, including phased implementation, multidisciplinary collaboration, capacity building and adaptation of international guidelines to local realities.
Through case-based examples, speakers will highlight measurable outcomes, quality and safety considerations and long-term program sustainability. By openly sharing challenges, lessons learned and practical insights, this session aims to provide actionable guidance for radiation oncology teams working in LMICs who seek to implement new technologies while maintaining high standards of care in resource-limited environments.
Learning Objectives:
- Describe successful institutional projects that demonstrate the implementation of advanced radiotherapy techniques in low- and middle-income countries, highlighting key factors that contributed to their success.
- Analyze practical tools, strategies and resource-adapted approaches used to implement radiotherapy technologies in middle- and low-income settings, considering clinical, technical and organizational constraints.
- Determine evidence-based recommendations and actionable strategies to overcome common barriers to implementation and to support the successful adoption and sustainability of new radiotherapy technologies in resource-limited environments.read more · Original Link ↗
M. Dolores De La Mata Moya, MD, PhD, MPHModerator - Centro Medico ABC
☆
Tue Sep 29 · 12:30 PM - 1:45 PM
SS 28 - From Data to Decisions: AI That Changes How We Treat Patients
Benjamin Rosen, PhD, DABRModerator - University of Michigan
Ying Xiao, PhD, FASTROModerator - University of Pennsylvania
☆
Tue Sep 29 · 12:30 PM - 1:45 PM
EDU 39 - Handling CNS Metastases in Sick Patients
● Education
📍 Room 256
Management of CNS metastases requires nuance with respect to patient performance status, comorbid conditions, extracranial disease status and concurrent systemic therapies.Management of CNS metastases requires nuance with respect to patient performance status, comorbid conditions, extracranial disease status and concurrent systemic therapies. Situations become more complicated for inpatients at end of life, when even a 5-fraction course could delay discharge to hospice. Acceptable options may vary from 1-2 fractions of whole brain RT to SRS for dominant lesions to no RT at all. Our panel will review these options in detail, with the decision process associated in each case. Dr. Hoskin will discuss situations where no CNS-directed therapy may be defensible and, in the patient's best interest. Dr. Keit will discuss data supporting 1-2 fraction courses of WBI in appropriate populations. Dr. Soliman will discuss a directed option of SRS to dominant lesions.
Learning Objectives:
- Discuss specific nuances complicating care of inpatients at end of life with CNS metastases.
- Differentiate between therapeutic RT options versus supportive care alone for patients at end of life.read more · Original Link ↗
Emily Keit, MDModerator - Moffitt Cancer Center
☆
Tue Sep 29 · 12:30 PM - 1:45 PM
EDU 41 - Harnessing the Microbiome in Low-Dose Radiation to Shape Tumor and Immune Responses
● Education
📍 Room 160
Emerging research shows that the microbiome plays a critical role in shaping tumor responses and anti-tumor immunity during radiation therapy.Emerging research shows that the microbiome plays a critical role in shaping tumor responses and anti-tumor immunity during radiation therapy. This session will highlight novel mechanisms by which the microbiome interacts with radiation to influence both tumor biology and immune responses, moving beyond classical microbiome-radiation discussions that focus primarily on toxicity or high-dose effects. Talks will cover low-dose radiation and immune modulation, tumor-intrinsic microbiome effects, and microbiome-immune crosstalk shaping tumor responses. Attendees will gain insight into forward-looking concepts and translational opportunities at the intersection of radiation therapy, the microbiome and immunity.
Learning Objectives:
- Describe the role of low-dose radiation in modulating immune responses in the context of microbiome interactions.
- Summarize tumor-intrinsic and immune-mediated mechanisms by which the microbiome regulates radiation sensitivity.read more · Original Link ↗
LeMoyne Habimana-Griffin, MD, PhDModerator - University of Wisconsin - Madison, Department of Human Oncology
☆
Tue Sep 29 · 12:30 PM - 1:45 PM
SS 29 - Intensify, Shorten, or Personalize? Modern Approaches to Post-prostatectomy RT
Sean McBride, MD, MPHModerator - Memorial Sloan Kettering Cancer Center
Shalini Moningi, MDModerator - Cleveland Clinic Taussig Cancer Institute
☆
Tue Sep 29 · 12:30 PM - 1:45 PM
EDU 40 - Liquid Biopsy: ctDNA in Early Stage and Metastatic Breast Cancer
● Education
📍 Room 205
The role of ctDNA in breast cancer is constantly evolving and expanding. This session will cover a number of topics: 1) Review the current technologies for liquid biopsy in breast cancer. 2) ctDNA in Early Breast Cancer a.The role of ctDNA in breast cancer is constantly evolving and expanding. This session will cover a number of topics: 1) Review the current technologies for liquid biopsy in breast cancer. 2) ctDNA in Early Breast Cancer a. rates of ctDNA detection in early stage breast cancer at diagnosis, pre- and post- neoadjuvant chemotherapy, and in the adjuvant setting. b. the utility of ctDNA in detecting MRD and predicting relapse in the adjuvant setting. c. the lead time between ctDNA detection and clinical relapse d. ongoing therapeutic trials using ctDNA in the adjuvant period. 3) ctDNA in stage IV breast cancer. a. uses of ctDNA to track disease and modify therapy b. radiation effect on ctDNA and ongoing trials in this space.
Learning Objectives:
- Have a better understanding of the role of ctDNA in early stage breast cancer.
- Have a better understanding of the role of ctDNA in metastatic breast cancer.
- Have a better understanding of how radiation may affect ctDNA levels and ongoing studies in this space.read more · Original Link ↗
Naamit Gerber, MDModerator - NYU Langone Medical Center
☆
Tue Sep 29 · 12:30 PM - 1:45 PM
SS 31 - Mechanisms of Resistance and Normal Tissue Toxicity
Philip Schaner, MD, PhDModerator - Dartmouth-Hitchcock Medical Center
Yvonne Mowery, MD, PhD, BSModerator - University of Pittsburgh Medical Center
☆
Tue Sep 29 · 12:30 PM - 1:45 PM
PQA 05 - Physics
● Poster Q & A
In Person Only
📍 Poster Hall - Exhibit Hall A
ASTRO's posters feature the latest scientific case studies, practice innovations and research from experts in the field of radiation oncology. In this session, in-person attendees will have the opportunity to ask poster presenters questions about their research.ASTRO's posters feature the latest scientific case studies, practice innovations and research from experts in the field of radiation oncology. In this session, in-person attendees will have the opportunity to ask poster presenters questions about their research.
This event is in-person only and will not be livestreamed or available onDemand.read more · Original Link ↗
☆
Tue Sep 29 · 12:30 PM - 1:45 PM
EDU 42 - Radiation Wins: New Evidence and Evolving Strategies in Multiple Myeloma
● Education
📍 Room 204
Dramatic innovations in systemic and inmunotherapy dramatically lengthened the survival of myeloma patients that could potentially benefit from local therapy. Yet, radiotherapy use remained stale and suppressed.Dramatic innovations in systemic and inmunotherapy dramatically lengthened the survival of myeloma patients that could potentially benefit from local therapy. Yet, radiotherapy use remained stale and suppressed.
More recently, emerging data of RT usage and efficacy in MM, supports a shift away from viewing RT as "palliation only" toward a more strategic role in the era of CAR T-cell therapy and bispecific antibodies. New datasets challenge long-standing assumptions regarding dose and fractionation, highlight the importance of timely and efficient local control for symptomatic, high-risk or refractory sites of disease, and raise questions about earlier intervention for extramedullary disease and oligoprogression - settings in which RT may meaningfully improve outcomes without compromising systemic therapy delivery.
This session will bring together expert speakers representing all relevant modalities (radiation oncology, hematology and imaging) who were directly involved in the pivotal studies. Attendees will leave with actionable guidance on patient selection, integration with novel systemic therapies, contemporary RT dosing/fractionation, toxicity mitigation and future trial directions.
Learning Objectives:
- Apply contemporary randomized data to identify when and how radiation therapy adds measurable value within multidisciplinary care, particularly in the context of novel systemic therapies.
- Communicate the role and benefits of radiation therapy more effectively to multidisciplinary partners, supporting aligned decision making that improves outcomes while minimizing toxicity.read more · Original Link ↗
Joachim Yahalom, MD, FASTROModerator - Memorial Sloan Kettering Cancer Center
Built for you by(617)-PATRICK, Champion AI speaker
This session offers practical, physician-led approaches to overcoming hidden barriers to clinical trial enrollment.This session offers practical, physician-led approaches to overcoming hidden barriers to clinical trial enrollment. Instead of simply recommending best practices, participants will see real-world examples such as initial meetings with patient advocates, integrating trial conversations into routine clinic visits, using scripts to build patient trust, and partnering with community leaders without the need for large grants or formal agreements. The focus is on actionable strategies that clinicians can adopt on a small scale to broaden trial participation and foster inclusivity.
This event is in-person only and will not be livestreamed or available onDemand.read more · Original Link ↗
Michelle Ludwig, MD, PhD, MPH, FASTROModerator - University of Colorado Health
Lydia Wilson, PhD, MSModerator - Thomas Jefferson University
EC 10 - Balancing Parenthood and Professional: Family Leave and Pathways to Family Building
● Special Session
In Person Only
📍 Northeast Lobby B and Room 155 - Early Career and Mentoring Lounge
An interactive discussion designed to connect residents, early-career professionals, and established practitioners around topics related to family planning, parenthood, fertility, adoption, and career development in radiation oncology.An interactive discussion designed to connect residents, early-career professionals, and established practitioners around topics related to family planning, parenthood, fertility, adoption, and career development in radiation oncology. Participants will engage directly with faculty facilitators in small-group discussions focused on shared experiences, resources, and practical strategies for balancing professional and family life.
This event is in-person only and will not be livestreamed or available onDemand.read more · Original Link ↗
International 05 - Reirradiation in Radiation Oncology: A Latin American Perspective on Biology, Technology and Clinical Decision Making (Session in Spanish)
● Education
📍 Room 204
Reirradiation represents one of the most complex and rapidly evolving areas in contemporary radiation oncology and requires a solid understanding of radiobiological principles, cumulative dose effects and normal tissue tolerance.Reirradiation represents one of the most complex and rapidly evolving areas in contemporary radiation oncology and requires a solid understanding of radiobiological principles, cumulative dose effects and normal tissue tolerance. In Latin America, increasing life expectancy, together with advances in early cancer detection and oncologic treatments, has resulted in a growing population of long-term cancer survivors. As a result, local and regional recurrences after prior radiotherapy are being encountered with increasing frequency in routine clinical practice.
In this context, reirradiation may offer meaningful disease control or curative potential when applied using rigorous criteria for patient selection, treatment planning and safety. This education session will provide a critical, evidence-based review of reirradiation strategies across several clinically relevant disease sites: brain tumors, prostate cancer, head and neck malignancies and rectal cancer. Evidence from prospective studies, large retrospective series, and international consensus guidelines will be integrated, with particular emphasis on applicability in resource-variable health care systems.
The session will begin with a moderator-led overview of the fundamental principles of reirradiation and the current landscape in Latin America, including access to technology, availability of advanced techniques, immobilization standards, imaging resources and protocol implementation. All subsequent presentations will follow a standardized, case-based format, starting with a representative clinical case and followed by a structured topic review based on current evidence, clinical experience and adaptation to available resources. Emphasis will be placed on advanced radiotherapy techniques (IMRT, VMAT, SRS, SBRT), dose summation strategies, and balancing therapeutic benefit, patient longevity, and short- and long-term toxicity.
Learning Objectives:
- Explain the key radiobiological principles and cumulative dose considerations that guide safe and effective reirradiation across different disease sites in Latin American clinical practice.
- Apply evidence-based planning, dose summation and advanced delivery strategies (IMRT, VMAT, SRS, SBRT) to optimize tumor control while minimizing acute and late toxicity in resource-variable environments.read more · Original Link ↗
Lina Loaiza, MDModerator - Clínica somer
☆
Tue Sep 29 · 2:15 PM - 3:15 PM
SS 06 - Musculoskeletal Tumors and Skeletomuscular Toxicities
Subha Perni, MDModerator - MD Anderson Cancer Center
☆
Tue Sep 29 · 2:15 PM - 3:30 PM
International 06 - CT-Guided, MRI-Guided, or Offline Adaptive Radiation Therapy? A Structured, Case-Based Debate on Value, Efficiency and Use across Global Resource Settings
● Education
📍 Room 156
Adaptive radiation therapy encompasses a spectrum of approaches that have evolved from historically established offline strategies to contemporary online CT-guided and MRI-guided adaptive platforms.Adaptive radiation therapy encompasses a spectrum of approaches that have evolved from historically established offline strategies to contemporary online CT-guided and MRI-guided adaptive platforms. Offline adaptive radiation therapy, widely used in routine clinical practice, relies on periodic reassessment and plan modification over days to weeks and typically requires no additional capital investment beyond standard imaging and planning infrastructure. In contrast, online adaptive approaches, whether CT-guided or MRI-guided, enable same-day plan modification at the treatment console but require substantially greater technological, staffing and financial resources.
This case-based, debate-style educational session will compare CT-guided online adaptive radiation therapy, MRI-guided adaptive radiation therapy, and offline adaptive strategies using representative clinical scenarios. Through structured point-counterpoint discussions, faculty will examine technical requirements, workflow efficiency, time to adaptation, disease-site-specific indications, and supporting clinical evidence for each approach. Particular emphasis will be placed on value, cost-effectiveness, and feasibility across diverse practice environments, including limited-resource and global oncology settings. By juxtaposing established and emerging adaptive paradigms, this session provides a practical framework to guide adaptive therapy selection based on clinical need, institutional capacity, and equitable access to high-quality care.
Learning Objectives:
- Compare CT-guided online adaptive, MRI-guided adaptive, and offline adaptive radiation therapy approaches with respect to technical requirements, workflow efficiency, time to adaptation, and resource utilization across diverse clinical practice settings.
- Determine appropriate clinical indications for each adaptive radiation therapy approach by integrating disease-site-specific considerations, anticipated clinical benefit, institutional capabilities, and patient-specific factors.
- Apply value-based decision making principles to select and justify an adaptive radiation therapy strategy that balances clinical benefit, operational feasibility, and cost-effectiveness, including in limited-resource and global oncology settings.read more · Original Link ↗
Tamer Refaat, MD, PhD, MSModerator - Loyola University Chicago
☆
Tue Sep 29 · 2:15 PM - 3:30 PM
EDU 44 - Claims-Based Research in Radiation Oncology: Emerging Methods and Contemporary Results
● Education
📍 Room 109
Using administrative claims data routinely collected for billing purposes, investigators have access to a wealth of health care utilization and health outcomes information for large populations.Using administrative claims data routinely collected for billing purposes, investigators have access to a wealth of health care utilization and health outcomes information for large populations. For studies of cancer treatment safety, these data can be used to compare toxicities between treatment regimens or study adverse events that have never been formally evaluated in a prospective trial. For health services research, these data can be used to assess disparities, inefficiencies in health care delivery, and the financial impact of different treatment strategies.
This session will provide radiation oncologists with background in the methods and contemporary applications of claims-based research. Attendees will understand how to evaluate data sources (e.g., SEER-Medicare) for appropriateness, critically appraise results of studies of health care disparities and treatment efficacy/safety, and design their own future studies.
Learning Objectives:
- Describe the strengths and limitations of using claims data in radiation oncology research.
- Determine the appropriate tools for utilizing claims to answer their research questions.
- Design their own study of radiation therapy policy, economics or safety using claims.read more · Original Link ↗
Shane Neibart, MD, MSModerator - Harvard Radiation Oncology Program
☆
Tue Sep 29 · 2:15 PM - 3:30 PM
EDU 43 - Contemporary Management of High-Risk Cutaneous Squamous Cell Carcinoma: Evidence-Based Integration of Adjuvant Immunotherapy and Radiotherapy
● Education
📍 Room 205
High-risk cutaneous squamous cell carcinoma (cSCC) presents increasing therapeutic complexity as practice-changing adjuvant immunotherapy data emerge alongside evolving radiotherapy strategies for an aging patient population.High-risk cutaneous squamous cell carcinoma (cSCC) presents increasing therapeutic complexity as practice-changing adjuvant immunotherapy data emerge alongside evolving radiotherapy strategies for an aging patient population. This multidisciplinary, case-based session will examine contemporary management of high-risk cSCC, focusing on the evidence-based integration of adjuvant immunotherapy and hypofractionated radiotherapy.
A multidisciplinary panel will review representative clinical cases to highlight modern approaches to risk stratification, postoperative decision making, and multidisciplinary coordination. Emphasis will be placed on identifying appropriate candidates for adjuvant immunotherapy and on optimally sequencing and integrating immunotherapy with radiotherapy.
Radiation-focused discussion will emphasize practical treatment-planning strategies, including target delineation and fractionation selection. The role of hypofractionated radiotherapy in elderly and medically frail patients will be explored, with attention to maintaining durable local-regional control while minimizing toxicity and treatment burden. Through representative cases, this session will provide actionable guidance for integrating immunotherapy and hypofractionated radiotherapy into multidisciplinary care for high-risk cSCC.
Learning Objectives:
- Interpret key findings from pivotal adjuvant immunotherapy trials and apply them to patient selection for adjuvant treatment in high-risk cutaneous squamous cell carcinoma.
- Integrate adjuvant immunotherapy with radiotherapy in a multidisciplinary treatment framework, including considerations of sequencing and radiotherapy planning strategies.
- Evaluate the role of hypofractionated radiotherapy in elderly and medically frail patients, balancing efficacy, toxicity and quality-of-life considerations.read more · Original Link ↗
Edina Wang, MDModerator - Duke University Medical Center
☆
Tue Sep 29 · 2:15 PM - 3:30 PM
PQA 06 - Genitourinary Cancer, Gynecological Cancer, and Health Care Access and Engagement
● Poster Q & A
In Person Only
📍 Poster Hall - Exhibit Hall A
ASTRO's posters feature the latest scientific case studies, practice innovations and research from experts in the field of radiation oncology. In this session, in-person attendees will have the opportunity to ask poster presenters questions about their research.ASTRO's posters feature the latest scientific case studies, practice innovations and research from experts in the field of radiation oncology. In this session, in-person attendees will have the opportunity to ask poster presenters questions about their research.
This event is in-person only and will not be livestreamed or available onDemand.read more · Original Link ↗
Jessica Frakes, MDModerator - Moffitt Cancer Center
Kyle Cuneo, MDModerator - University of Michigan
☆
Tue Sep 29 · 2:15 PM - 3:30 PM
EDU 46 - Perioperative Immunotherapy in Head and Neck Cancer: Trial Data, Real-World Practice and Radiation Oncology Implications
● Education
📍 Room 107
For the first time in two decades, two pivotal randomized trials (KEYNOTE 689 and NIVOPOSTOP) have proposed a new therapeutic regimen which demonstrated superiority over standard of care chemoradiation in patients with locally advanced, surgically resectable head and neck squamous...For the first time in two decades, two pivotal randomized trials (KEYNOTE 689 and NIVOPOSTOP) have proposed a new therapeutic regimen which demonstrated superiority over standard of care chemoradiation in patients with locally advanced, surgically resectable head and neck squamous cell carcinoma. Perioperative immunotherapy is now incorporated within NCCN guidelines and FDA approved for head and neck cancer patients whose tumors express PD-L1. While perioperative immunotherapy is reshaping the treatment paradigm in resectable head and neck cancer, many questions remain and new challenges arise. For example, what is the ideal timing for adding immunotherapy (neoadjuvant, adjuvant, or both)? How does one approach perioperative management for oral cavity patients versus other head and neck subsites? How does perioperative immunotherapy influences decisions about treatment volumes both surgically and from the radiation oncology perspective? In this session, we bring together a multidisciplinary panel including a radiation oncologist (from the NIVOPOSTOP trial), medical oncologist (from the KEYNOTE-689 trial) and surgical oncologist who is also a leading expert in cancer immunotherapy. Through a series of short lectures and case-based discussions, the panel will present recent pivotal data, explore current knowledge gaps and discuss best clinical practices.
Learning Objectives:
- Review recent pivotal data and explore current knowledge gaps on perioperative immunotherapy for head and neck cancers.
- Discuss best clinical practices when incorporating immunotherapy into standard of care for head and neck cancer.
- Assess how perioperative immunotherapy influences decisions around radiation planning.read more · Original Link ↗
Carmen Kut, MD, PhDModerator - Johns Hopkins
☆
Tue Sep 29 · 2:15 PM - 3:30 PM
EDU 45 - Photon-Counting CT in Radiotherapy: From Imaging Innovation to Clinical Impact
● Education
📍 Room 157
Photon-counting CT (PCCT) has recently become commercially available in diagnostic radiology and represents a major advance in x-ray imaging technology. By providing energy-resolved, quantitative imaging data with improved spatial resolution and noise performance, PCCT holds significant potential for radiation oncology.Photon-counting CT (PCCT) has recently become commercially available in diagnostic radiology and represents a major advance in x-ray imaging technology. By providing energy-resolved, quantitative imaging data with improved spatial resolution and noise performance, PCCT holds significant potential for radiation oncology. Emerging applications include improved target and organ-at-risk delineation, more accurate material composition and electron or stopping-power estimation for dose calculation, particularly relevant for particle therapy, as well as enhanced outcome analysis for biologically or functionally informed adaptive radiotherapy strategies.
As PCCT is a new and rapidly evolving technology, its introduction into radiotherapy requires a careful and informed assessment of both its opportunities and challenges. Understanding how PCCT data can be translated into clinically actionable information, how it integrates into existing simulation and planning workflows, and what technical, clinical and operational adaptations are needed will be essential for successful adoption. Equally important is establishing a shared language to communicate the value and limitations of PCCT across physicians, physicists and other stakeholders.
This education symposium will bring together experts in medical physics, imaging science and clinical radiation oncology to review the fundamental principles of PCCT, discuss emerging radiotherapy applications and examine practical considerations for implementation. Through interdisciplinary perspectives, the session aims to stimulate discussion, clarify clinical decision making pathways informed by PCCT data, and foster collaboration to guide the thoughtful integration of this technology into future radiotherapy practice.
Learning Objectives:
- Understand the fundamental principles of photon-counting CT technology and how it differs from conventional energy-integrating CT systems in terms of data acquisition and image formation.
- Assess current and emerging applications of photon-counting CT in radiation oncology, and its potential clinical value and future directions.
- Recognize the limitations, challenges and uncertainties associated with implementing photon-counting CT in radiotherapy.read more · Original Link ↗
Xun Jia, PhDModerator - Johns Hopkins University School of Medicine
☆
Tue Sep 29 · 2:15 PM - 3:30 PM
SS 37 - Radiation-Immune Crosstalk in Tumor and Normal Tissue Response
Indrin Chetty, PhD, MS, FASTROModerator - Cedars-Sinai Medical Center
Nirav Kapadia, MD, MSModerator - Dartmouth-Hitchcock Medical Center
☆
Tue Sep 29 · 2:15 PM - 4:15 PM
Workshop 08 - Grant Writing Workshop
● Workshop
📍 Room 153
The session is designed to provide residents, trainees and junior faculty with information on grant writing. It will provide educational information followed by an interactive breakout session.The session is designed to provide residents, trainees and junior faculty with information on grant writing. It will provide educational information followed by an interactive breakout session. Topics will include review criteria, crafting specific aims, developing a research strategy, and revising and resubmitting grants. Breakout sessions will be divided by topic area and allow participants to get specific feedback on their ideas.
Learning Objectives:
- Analyze strengths, weaknesses and pitfalls of writing grant proposals.
- Discuss the key elements of a grant proposal.
- Understand the revision and resubmission process.read more · Original Link ↗
Debra Yeboa, MDModerator - MD Anderson Cancer Center
Built for you by(617)-PATRICK, Champion AI speaker
This hands-on session provides a small-group educational experience focused on the delivery of radiopharmaceutical therapy (RPT). Participants will observe expert-led demonstrations and engage with RPT clinicians and equipment while exploring clinical workflows, operational considerations, and safety practices associated with RPT.This hands-on session provides a small-group educational experience focused on the delivery of radiopharmaceutical therapy (RPT). Participants will observe expert-led demonstrations and engage with RPT clinicians and equipment while exploring clinical workflows, operational considerations, and safety practices associated with RPT. In-kind support for this session is provided by Novartis and Capintec, A Mirion Medical Company.
This event is in-person only and will not be livestreamed or available onDemand.read more · Original Link ↗
Angela Carmona (Senior Publisher, Elsevier) will be available to discuss publishing and any questions you may have during ASTRO's Annual Meeting.Angela Carmona (Senior Publisher, Elsevier) will be available to discuss publishing and any questions you may have during ASTRO's Annual Meeting. Some topics could include tools and resources for authors, editors, and reviewers; how the peer review and publication process work; publishing open access; understanding ethics and best practices; and more.
This event is in-person only and will not be livestreamed or available onDemand.read more · Original Link ↗
QP 21 - Innovating With Software to Drive Patient Safety & Quality
● Quick Pitch
📍 Room 256
Quick Pitch sessions provide opportunities for presenters to summarize outcomes while highlighting key takeaways from their research in a fast-paced format to present concise takeaways. · Original Link ↗
Raymond Mak, MDModerator - Brigham and Women's Hospital/Dana-Farber Cancer Institute
Kelly Paradis, PhDModerator - University of Michigan
☆
Tue Sep 29 · 3:45 PM - 4:45 PM
QP 24 - Novel Delivery, Metabolism, and Immune Modulation
● Quick Pitch
📍 Room 160
Quick Pitch sessions provide opportunities for presenters to summarize outcomes while highlighting key takeaways from their research in a fast-paced format to present concise takeaways. · Original Link ↗
Prasanna Alluri, MD, PhDModerator - UT Southwestern Medical Center
Lisa Sudmeier, MD, PhDModerator - Emory University Winship Cancer Institute
☆
Tue Sep 29 · 3:45 PM - 4:45 PM
QP 23 - Radiotherapy for Nonmalignant Conditions
● Quick Pitch
📍 Room 107
Quick Pitch sessions provide opportunities for presenters to summarize outcomes while highlighting key takeaways from their research in a fast-paced format to present concise takeaways. · Original Link ↗
Yi An, MDModerator - Yale University
Varun Chowdhry, MD, MBAModerator - Roswell Park Comprehensive Cancer Center
☆
Tue Sep 29 · 3:45 PM - 4:45 PM
QP 03 - Right Care, Right Cost: Access and Utilization in Oncology
● Quick Pitch
📍 Room 109
Quick Pitch sessions provide opportunities for presenters to summarize outcomes while highlighting key takeaways from their research in a fast-paced format to present concise takeaways. · Original Link ↗
Onyinye Balogun, MD, MSModerator - Northwell Health Cancer Institute
Trevor Royce, MD, MS, MPHModerator - University of North Carolina
☆
Tue Sep 29 · 3:45 PM - 5:00 PM
EDU 49 - Beyond the Nodes: A Practical Guide to Extranodal Lymphomas
● Education
📍 Room 204
Extranodal lymphoma radiotherapy varies widely based on anatomic site, histology and systemic therapy context. The introductory talk will provide a clear, high-level overview of extranodal lymphomas, focusing on common clinical scenarios radiation oncologists encounter in practice.Extranodal lymphoma radiotherapy varies widely based on anatomic site, histology and systemic therapy context. The introductory talk will provide a clear, high-level overview of extranodal lymphomas, focusing on common clinical scenarios radiation oncologists encounter in practice. It will review how radiotherapy dose and field design have evolved over time and how treatment approaches differ between more frequent presentations (such as orbit and gastric lymphoma) and higher-risk or immune-privileged sites, setting a practical framework for clinical decision making.
Breast lymphoma, while uncommon, presents real-world challenges in determining how to deliver radiotherapy. The second talk will review typical presentations and patterns of relapse, summarize the evidence supporting radiotherapy in breast lymphoma, and provide practical guidance on dose selection, target volumes and coordination with systemic therapy. Emphasis will be placed on applying available data to everyday practice while minimizing toxicity and unnecessary treatment.
Testicular lymphoma is a classic sanctuary-site disease in which radiotherapy remains a key component of care, yet questions persist regarding set-up, planning and integration with systemic and CNS-directed therapy. Radiotherapy effects on testosterone levels and monitoring guidance will be provided. The final talk will translate foundational evidence into actionable recommendations, highlighting common pitfalls and best practices that radiation oncologists can readily implement across practice settings.
Together, these talks aim to reduce practice variability by offering a straightforward, evidence-based approach to extranodal lymphomas, providing attendees with practical tools they can apply immediately while also contextualizing ongoing areas of uncertainty and evolution in the field.
Learning Objectives:
- Describe the spectrum of extranodal lymphomas and the evolution of radiotherapy dose and field design across indolent, aggressive and immune-privileged sites - highlighting how biology, anatomic site (e.g., orbit, stomach, CNS) and systemic therapy integration inform contemporary treatment selection and set the framework for site-specific management.
- To differentiate between the clinical presentations and management options for common histological subtypes of primary breast lymphoma and recognize the different management of breast transplant related lymphomas.
- Explain the rationale, indications and technical considerations for testicular radiotherapy in testicular lymphoma, including patterns of failure, dose selection and integration with systemic and CNS-directed therapy.read more · Original Link ↗
George Mikhaeel, MD, MBBSModerator - Guy's and St. Thomas' NHS Foundation Trust
☆
Tue Sep 29 · 3:45 PM - 5:00 PM
International 07 - Challenges of Developing a Radiation Oncology Program in a LMIC Country: The Tale of Four Centers
● Storytelling
📍 Room 258
This session will describe the journey faced by four different organizations in developing a radiation oncology center in a low-to-middle income country: one in Georgia, one in Mexico, one in Tanzania, Africa, and one in Cameroon, Africa.This session will describe the journey faced by four different organizations in developing a radiation oncology center in a low-to-middle income country: one in Georgia, one in Mexico, one in Tanzania, Africa, and one in Cameroon, Africa. It will compare and contrast the various challenges that were faced, three being private hospitals (Krystyna Kiel Oncology Center in Georgia, Mbingo Hospital in Cameroon and Kilimanjaro Christian Medical Center in Tanzania) and the other being a public hospital (Centro Estatal de Cancerologia Dr. Dorantes Mesa in Xalapa, Veracruz, Mexico).
Learning Objectives:
- Describe the challenges faced by low-middle income countries in establishing radiation oncology programs.
- Assess what role you can play in helping to establish or support these programs.read more · Original Link ↗
Linda Grossheim, MD, MSModerator - Beacon Cancer Center
☆
Tue Sep 29 · 3:45 PM - 5:00 PM
EDU 50 - Establishing a National Quality Assurance Framework for Brachytherapy Trials: An Unmet Need
● Education
📍 Room 157
Standardization in treatment planning and delivery for radiation therapy (RT) is critical for multi-institutional clinical trials. Without it, trial results risk inconsistency and reduced reliability.Standardization in treatment planning and delivery for radiation therapy (RT) is critical for multi-institutional clinical trials. Without it, trial results risk inconsistency and reduced reliability. External beam RT trials have long benefited from robust credentialing and quality assurance (QA) programs such as benchmark cases, dummy runs, pre-treatment and on treatment reviews, and structured data management, which have demonstrably improved trial integrity and patient outcomes.
In stark contrast, brachytherapy (BT) trials in the U.S. lack a unified QA infrastructure. This gap leaves essential BT processes such as imaging, contouring, applicator reconstruction, treatment planning, quality evaluation and dose reporting fragmented and inconsistent. Given the complexity and human-factor dependency of BT procedures, the absence of standardization compromises reproducibility and patient safety. The urgency for a robust QA program is further highlighted by rapid advancements in BT applicator technology, muti-imaging modalities, model-based dose calculations and real-time tracking.
Recognizing this unmet need, AAPM Task Group 425 (TG-425) has been formed in collaboration with NRG, IROC, ABS and EFOMP to establish a structured QA framework for BT trials.
We will present ongoing efforts by TG-425, addressing current gaps in BT trial QAs, outline a comprehensive BT QA workflow, and explore the role of artificial intelligence (AI) in enhancing trial QA processes. Ultimately, our goal is to provide practical guidance for multi-disciplinary teams including trial designers, QA centers, and participating institutions on adopting standardized BT QA programs, from trial activation through post-treatment data management, ensuring consistency, safety and scientific rigor in future BT trials.
Learning Objectives:
- Explain QA gaps and best practices regarding BT clinical trials.
- Identify key components of a robust BT specific quality assurance (QA) program from trial activation to post treatment for BT clinical trials across the multi-disciplinary team.
- Apply guidance for enhancing brachytherapy trial quality using a structured QA framework and emerging AI applications.read more · Original Link ↗
Hayeon Kim, PhDModerator - Magee Womens Hospital of University of Pittsburgh Medical Center
☆
Tue Sep 29 · 3:45 PM - 5:00 PM
SS 40 - Evolving Paradigms in High-Risk Breast Cancer: Optimization and Integration of Treatment Modalities Across the Disease Continuum
Corey Speers, MD, PhDModerator - University of Alabama Birmingham School of Medicine
Jana Fox, MDModerator - Montefiore Medical Center
☆
Tue Sep 29 · 3:45 PM - 5:00 PM
PQA 07 - Head and Neck Cancer, Lung Cancer/Thoracic Malignancies, and Nursing and Supportive Care
● Poster Q & A
In Person Only
📍 Poster Hall - Exhibit Hall A
ASTRO's posters feature the latest scientific case studies, practice innovations and research from experts in the field of radiation oncology. In this session, in-person attendees will have the opportunity to ask poster presenters questions about their research.ASTRO's posters feature the latest scientific case studies, practice innovations and research from experts in the field of radiation oncology. In this session, in-person attendees will have the opportunity to ask poster presenters questions about their research.
This event is in-person only and will not be livestreamed or available onDemand.read more · Original Link ↗
☆
Tue Sep 29 · 3:45 PM - 5:00 PM
EDU 48 - Improving Disability Inclusion in Radiation Oncology, From Theory to Clinic
● Education
📍 Room 257
Accessibility is a critical yet underrecognized determinant of quality, safety, and equity in radiation oncology.Accessibility is a critical yet underrecognized determinant of quality, safety, and equity in radiation oncology. Patients and providers with physical, sensory, cognitive and communication disabilities routinely encounter barriers throughout the radiation therapy care continuum, from consultation and simulation to treatment delivery and follow-up. This multidisciplinary education session will equip radiation oncology professionals with conceptual frameworks and practical tools to identify and address these barriers in clinical practice. The first speaker, a medical physicist and chair of the AAPM Accessibility Subcommittee, will provide clear definitions of disability and accessibility and introduce a structured framework for understanding disability from both provider and patient perspectives. This speaker will introduce the concept of universal design and discuss how proactively designing systems, workflows and environments for diverse abilities can improve safety and care quality for all patients. The second speaker, a patient advocate who has undergone radiation with a physical disability, will discuss strategies to partner with patients to design care to remove accessibility barriers. The third speaker, a radiation oncology nurse and patient advocate, will draw on her lived experience of disability to highlight common, often overlooked barriers faced by patients in radiation oncology clinics. She will describe the development of a departmental accessibility task force as a practical tool for identifying gaps, engaging stakeholders and implementing sustainable accessibility improvements. The final speaker, a neuroscientist with a focus on accessibility design, will discuss potential technological and population-level means of addressing these disparities in practice.
Learning Objectives:
- Apply a structured framework to assess accessibility at their institution across the care continuum (consultation, simulation, treatment delivery and follow-up).
- Integrate universal design principles into decision making related to equipment use, staffing workflows, patient education materials and clinic layout.
- Initiate or participate in multidisciplinary efforts - such as a disability task force or quality improvement initiative - to address accessibility barriers at a departmental and/or national level.read more · Original Link ↗
Carlos Rodriguez-Russo, MDModerator - University of Minnesota
☆
Tue Sep 29 · 3:45 PM - 5:00 PM
EDU 51 - Mythbusting Radiation Oncology: Communicating the Truth and Value of Radiotherapy to the Public, Patients, Providers and Policymakers
● Education
📍 Room 259
Misinformation about radiation therapy persists in mainstream media, contributing to patient fears and misunderstanding. This session focuses on working with journalists to correct misinformation and elevate radiotherapy's visibility.Misinformation about radiation therapy persists in mainstream media, contributing to patient fears and misunderstanding. This session focuses on working with journalists to correct misinformation and elevate radiotherapy's visibility. Through perspectives from a media-engaged radiation oncologist, a health care journalist, and a patient advocate, attendees will learn how to craft clear messages, respond to inaccuracies, and proactively engage the press.
Despite major advances in precision, safety and clinical outcomes, many persistent myths - such as exaggerated fears about toxicity, confusion between therapeutic radiation and environmental exposure, or the belief that radiation is "old-fashioned" compared to systemic therapies - continue to shape public perception. These misconceptions are amplified when media coverage presents incomplete, outdated or sensationalized narratives. In recent years, several widely circulated stories have portrayed radiation in misleading ways.
Radiation oncologists rarely receive training in how to communicate with journalists, respond to misinformation, or proactively shape stories about cancer treatment. As a result, the specialty is underrepresented in lay media. This absence allows myths to persist unchallenged and deprives the public of accurate, balanced explanations of radiotherapy's role in modern cancer care.
Early career clinicians increasingly recognize the need to engage with the media, but many lack practical strategies, confidence or understanding of how journalists work. This session addresses these gaps by equipping attendees with skills to counter common myths, explain complex concepts in simple and compelling language, and collaborate effectively with media professionals. By strengthening the field's voice, radiation oncology can correct misinformation, empower patients and elevate the specialty's visibility.
Learning Objectives:
- Apply clear, engaging and evidence-based communication strategies to counter misinformation and explain radiotherapy concepts in ways that resonate with lay audiences.
- Develop confidence in preparing for media interactions, including interviews, background calls and rapid responses to inaccurate or sensationalized stories.
- Collaborate effectively with media professionals by understanding how stories are selected, framed and edited - and how clinicians can serve as trusted sources.read more · Original Link ↗
Avinash Chaurasia, MDModerator - Brooke Army Medical Center
Puneeth Iyengar, MD, PhDModerator - LSU Health Sciences Center New Orleans
☆
Tue Sep 29 · 3:45 PM - 5:00 PM
EDU 47 - Precision in Practice: The Use of Novel Biomarkers in GU Cancers
● Education
📍 Room 205
The incidence of three major genitourinary cancers including prostate cancer, bladder cancer and renal cell carcinoma, has substantially increased. Alongside surgical interventions, systemic therapies like chemotherapy, radiotherapy and hormone therapy are utilized in treating genitourinary cancers.The incidence of three major genitourinary cancers including prostate cancer, bladder cancer and renal cell carcinoma, has substantially increased. Alongside surgical interventions, systemic therapies like chemotherapy, radiotherapy and hormone therapy are utilized in treating genitourinary cancers. Nevertheless, these approaches face limitations stemming from tumor heterogeneity, clinical variability and drug resistance, often yielding unsatisfactory outcomes. Biomarkers play a pivotal role in early tumor diagnosis, drug development, disease monitoring and prognosis evaluation. Therefore, investigating potential urogenital tumor biomarkers will aid in identifying therapeutic targets, enhancing the efficacy of immune and targeted therapies, and bolstering comprehensive patient management for urogenital tumors.
Over the past five years, there have been large changes and advances in biomarkers for bladder, renal and prostate cancer. There has been an increased usage of biomarkers, for example, Decipher, Artera, ctDNA, VALOR labs etc. in prostate, bladder and renal cancers. Additionally, there is increased data supporting the role of biomarkers in treatment selection, de-escalation and/or intensification of treatment in multiple GU disease sites. The goal of this session will be to review the latest data in each disease site as well as provide some real-world patient examples and how to use biomarkers to help with treatment decision making.
Learning Objectives:
- Give learners the opportunity to increase their knowledge on the current available biomarkers in the GU space in bladder, renal and prostate cancer and appropriate clinical scenarios to use these biomarkers.
- Give learners the opportunity to increase their knowledge on data supporting the use of biomarkers in the treatment decision making for bladder, renal and prostate cancer.read more · Original Link ↗
Shalini Moningi, MDModerator - Cleveland Clinic Taussig Cancer Institute
☆
Tue Sep 29 · 3:45 PM - 5:00 PM
SS 36 - Predicting Benefit and Toxicity: Biomarkers in Prostate Radiotherapy
International 08 - ASTRO/CSCO Joint Session: AI-Enabled Radiation Therapy for Global Oncology: Practical Implementation for Cost Reduction
● Education
📍 Room 258
We will describe high-impact use cases of AI across the radiotherapy workflow, including deciphering EMR, analyzing imaging, generate automated contouring, planning or QA, and generating outcome modeling, with specific relevance to global practice.We will describe high-impact use cases of AI across the radiotherapy workflow, including deciphering EMR, analyzing imaging, generate automated contouring, planning or QA, and generating outcome modeling, with specific relevance to global practice. We will compare AI deployment models suitable for lower-resource environments (cloud vs. on-premise vs. hybrid; centralized planning hubs vs. site-based automation) and their tradeoffs for cost, workforce needs and reliability. We will identify key barriers and enabling infrastructure for safe AI adoption in LMIC radiotherapy programs, including data quality, IT systems, connectivity, cybersecurity and human factors. In addition, we will evaluate equity considerations - how to avoid "AI widening the gap" - including dataset bias, model drift and strategies for inclusive multicenter data collaboration and governance.
Learning Objectives:
- Know available AI options in health care and recognize the difference worldwide.
- Obtain basic understanding and know the steps to acquire AI solutions to bridge the gap based on resources available.read more · Original Link ↗
Meng Welliver, MD, PhDModerator - Mayo Clinic Alix School of Medicine
☆
Tue Sep 29 · 5:15 PM - 6:15 PM
QP 28 - Actionable Biomarkers: Guiding Therapy Selection and De-escalation
● Quick Pitch
📍 Room 205
Quick Pitch sessions provide opportunities for presenters to summarize outcomes while highlighting key takeaways from their research in a fast-paced format to present concise takeaways. · Original Link ↗
Michael Goldstein, MD, PhDModerator - Johns Hopkins School of Medicine
Alan Dal Pra, MDModerator - University of Miami - Sylvester Comprehensive Cancer Center
☆
Tue Sep 29 · 5:15 PM - 6:15 PM
QP 33 - Advances in Planning Algorithm and Optimization
● Quick Pitch
📍 Room 160
Quick Pitch sessions provide opportunities for presenters to summarize outcomes while highlighting key takeaways from their research in a fast-paced format to present concise takeaways. · Original Link ↗
Indrin Chetty, PhD, MS, FASTROModerator - Cedars-Sinai Medical Center
Victoria Yu, PhDModerator - Memorial Sloan Kettering Cancer Center
☆
Tue Sep 29 · 5:15 PM - 6:15 PM
QP 25 - Clinical Potpourri: Navigating Early-Stage RT, N1mi Disease, and Risk Mitigation in Triple Negative and HER2+ Breast Cancer
● Quick Pitch
📍 Room 253
Quick Pitch sessions provide opportunities for presenters to summarize outcomes while highlighting key takeaways from their research in a fast-paced format to present concise takeaways. · Original Link ↗
Neil Taunk, MD, MSModerator - University of Pennsylvania
Eileen Connolly, MD, PhDModerator - New York Presbyterian Hospital Columbia Campus
☆
Tue Sep 29 · 5:15 PM - 6:15 PM
EDU 55 - Data to Dollars: A Radiation Oncologist's Role in Advocating for the Financial Future of Our Patients and Our Field
● Education
📍 Room 109
Financial toxicity, defined by the NCI as, "the problems a patient has related to the cost of medical care," is a burden across all medical care.Financial toxicity, defined by the NCI as, "the problems a patient has related to the cost of medical care," is a burden across all medical care. Patients with cancer and their families are at increased risk of financial toxicity compared to other medical conditions. Estimates indicate up to half of patients diagnosed with cancer experience financial toxicity. High direct costs (driven by increasing costs of targeted and immunotherapies along with skyrocketing costs of insurance) alongside indirect costs such as transportation and extended time away from work, cumulatively lead to financial instability and worse outcomes for patients.
Over the last decade the understanding of and ability to assess patient's financial burden has taken leaps. This session puts into action the data driven research aimed at addressing the financial harm caused to patients and engages in active discussion of the cost-benefit of various approaches to cancer care, including the value and impact of radiotherapy. With current trends of rising health care costs and worsening coverage, this session demonstrates the impact of introducing validated short screening tools into the clinic to identify patients at financial risk. Attendees will be equipped with tools to start the conversation with patients, communities, providers and health care organizations toward highlighting both 1) the value that radiotherapy provides and 2) evidence-based strategies to ameliorate financial toxicity in patients.
Our expert panel will give attendees a deeper understanding of financial toxicity's harm and the value proposition of radiotherapy to reduce financial burden within the context of rising health care costs.
Learning Objectives:
- Discuss how different aspects of cancer treatment contribute to financial toxicity and the cost-effectiveness of radiation.
- Estimate the financial burden that patients will experience during and after their treatment using validated patient-reported outcome tools.
- Apply their understanding of financial toxicity to make improvements to the financial burden of patients at their institutions.read more · Original Link ↗
Alden D'Souza, MD, MPHSModerator - Washington University in St. Louis School of Medicine
☆
Tue Sep 29 · 5:15 PM - 6:15 PM
EDU 54 - Equipping the Clinician for the Latest in Management of Challenging Gliomas
● Education
📍 Room 162
This session will address the less common and challenging situations that clinicians face in glioma management. The classification of gliomas has become more complex, with increased emphasis on molecular features, alongside traditional histological findings.This session will address the less common and challenging situations that clinicians face in glioma management.
The classification of gliomas has become more complex, with increased emphasis on molecular features, alongside traditional histological findings. While newer entities have been recognized, optimal management strategies are less well defined, thus posing challenges for clinicians. This situation is further complicated when histological features do not align with molecular features. In nearly all patients, at the time of glioma recurrence, there is no standard management strategy. Reirradiation is recognized as a useful option in select patients, but there remains uncertainty as to how reirradiation is best applied.
This exciting and practical session will include presentations from experienced adult and pediatric Radiation Oncologists covering dedicated topics not previously addressed in prior CNS Education Sessions, with an emphasis on practical treatment planning guidance for practitioners. Topics to be covered include molecular glioblastoma and brainstem glioma with a focus on WHO classification updates and potential impact on management, practical considerations for treatment (including target volume definition and dose) and the role of systemic therapies. In addition, the timely topic of reirradiation in recurrent glioma will be comprehensively covered, including advanced imaging for confirmation of recurrence vs. treatment effect, target volume definition and dose, the role of bevacizumab and the latest trial evidence to support best practice.
The session aims to equip practitioners with an up-to-date, evidence-based approach for managing these complex and increasingly common situations.
Learning Objectives:
- Describe the place of molecular glioblastoma and brainstem glioma within WHO classification.
- Discuss evidence-based approaches for the management of molecular glioblastoma and brainstem glioma.
- Explain evidence-based strategies regarding the diagnosis and use of reirradiation for recurrent glioma.read more · Original Link ↗
Michelle Kim, MDModerator - University of Michigan
☆
Tue Sep 29 · 5:15 PM - 6:15 PM
QP 27 - Getting SMART About Ablative Radiation Therapy in Pancreaticobiliary Cancer and Liver Metastases
● Quick Pitch
📍 Room 259
Quick Pitch sessions provide opportunities for presenters to summarize outcomes while highlighting key takeaways from their research in a fast-paced format to present concise takeaways. · Original Link ↗
Aisling Barry, MBBS, MSc, FFR RCSI, FRCPCModerator - University College Cork
Andrzej Wojcieszynski, MDModerator - Colorado Permanente
☆
Tue Sep 29 · 5:15 PM - 6:15 PM
QP 30 - HPV-associated Oropharyngeal Cancer (HPVOPC): De-escalation, Volumes, and Outcomes
● Quick Pitch
📍 Room 157
Quick Pitch sessions provide opportunities for presenters to summarize outcomes while highlighting key takeaways from their research in a fast-paced format to present concise takeaways. · Original Link ↗
Yao Yu, MDModerator - Memorial Sloan Kettering Cancer Center
Anthony Apicelli, MD, PhDModerator - Washington University
☆
Tue Sep 29 · 5:15 PM - 6:15 PM
QP 31 - Medical Education/Professional Development Quick Pitch
● Quick Pitch
📍 Room 254
Quick Pitch sessions provide opportunities for presenters to summarize outcomes while highlighting key takeaways from their research in a fast-paced format to present concise takeaways. · Original Link ↗
Jonathan Klein, MD, MSModerator - SUNY Downstate Health Sciences University
Jie Jane Chen, MDModerator - The University of Texas MD Anderson Cancer Center
Quick Pitch sessions provide opportunities for presenters to summarize outcomes while highlighting key takeaways from their research in a fast-paced format to present concise takeaways. · Original Link ↗
Lydia Wilson, PhD, MSModerator - Thomas Jefferson University
Monica Krishnan, MDModerator - Brigham and Women's Hospital
☆
Tue Sep 29 · 5:15 PM - 6:15 PM
QP 29 - Response Assessment and Risk Stratification in Gynecologic Cancers: Biomarkers, Imaging, and Outcomes
● Quick Pitch
📍 Room 257
Quick Pitch sessions provide opportunities for presenters to summarize outcomes while highlighting key takeaways from their research in a fast-paced format to present concise takeaways. · Original Link ↗
Stephanie Markovina, MD, PhDModerator - Washington University
Christopher Weil, MD, MSModerator - MD Anderson Cancer Center
☆
Tue Sep 29 · 5:15 PM - 6:15 PM
EDU 53 - Rewriting Metastatic Biology With Radiotherapy: States, Immunity and CIN
● Education
📍 Room 107
Metastasis-directed radiotherapy (RT) has moved from an end-of-life palliation tool to an integral component of oligometastatic and oligoprogressive management.Metastasis-directed radiotherapy (RT) has moved from an end-of-life palliation tool to an integral component of oligometastatic and oligoprogressive management. Yet the field still lacks an integrated biological framework to predict when RT will change the metastatic trajectory versus merely debulk an index lesion. This session will translate emerging mechanistic data into clinically actionable insights across three domains: (i) metastatic states and microenvironmental dependencies that shape sensitivity to local ablation; (ii) immunologic consequences of RT in metastatic disease, including effects on T-cell priming, myeloid programs and lymphatic architecture that influence systemic control and interactions with immunotherapy; and (iii) chromosomal instability-driven inflammatory signaling that promotes metastatic fitness and may be amplified or therapeutically exploited by RT-induced DNA damage. Through expert talks and interactive audience polling, attendees will learn how these emerging mechanistic insights will dictate the future use of radiotherapy to modify the trajectory of metastatic disease to benefit patients. The goal is to move from data to dialogue, equipping radiation oncologists and trialists to communicate and deliver RT's value in metastatic care with greater biological precision.
Learning Objectives:
- Elucidate the role of radiotherapy in modifying clinical trajectory of oligometastic and oligoprogressive disease.
- Understand the positive and negative immunologic consequences of radiotherapy on the trajectory of metastatic cancer.
- Understand the interaction of chromosomal instability and radiotherapy on cellular signaling.read more · Original Link ↗
Jeremy Setton, MDModerator - Memorial Sloan Kettering Cancer Center
☆
Tue Sep 29 · 5:15 PM - 6:15 PM
QP 34 - Skin and Sarcoma Shorts: Clinical Highlights and Recent Advances
● Quick Pitch
📍 Room 210
Quick Pitch sessions provide opportunities for presenters to summarize outcomes while highlighting key takeaways from their research in a fast-paced format to present concise takeaways. · Original Link ↗
Katie Lee, MD, PhDModerator - Mayo Clinic Rochester
Andrew Bishop, MDModerator - UT MD Anderson Cancer Center
☆
Tue Sep 29 · 5:15 PM - 6:15 PM
EDU 52 - The Challenges of Thoracic Reirradiation
● Education
📍 Room 156
Thoracic reirradiation is a challenging and increasingly common scenario for radiation oncologists. In this session, we will review reirradiation guidelines via case discussions taken from our practice.Thoracic reirradiation is a challenging and increasingly common scenario for radiation oncologists. In this session, we will review reirradiation guidelines via case discussions taken from our practice. During this interactive session, attendees will review constraints for common organs at risk, dose discounting and best radiation techniques to utilize in various reirradiation scenarios.
Learning Objectives:
- Formulate a systematic framework to approach re-irradiation cases and determine the best strategy.
- Assess the optimal cumulative dose constraints for common organs at risk taking into account fractionation and dose discounting.read more · Original Link ↗
Yufei Liu, MD, PhDModerator - City of Hope National Medical Center
☆
Tue Sep 29 · 5:15 PM - 6:15 PM
QP 26 - The Right Patient, the Right Treatment: Machine Learning for Stratification and Prediction
● Quick Pitch
📍 Room 204
Quick Pitch sessions provide opportunities for presenters to summarize outcomes while highlighting key takeaways from their research in a fast-paced format to present concise takeaways. · Original Link ↗
Soumyajit Roy, MBBS, MSc.Moderator - University Hospitals Seidman Cancer Center
Jun Deng, PhD, FASTROModerator - Yale University
Built for you by(617)-PATRICK, Champion AI speaker
This year, ASTRO's cherished Gold Medal Dinner evolves into the Gold Medal Gala - a premier black-tie event for the field of radiation oncology.This year, ASTRO's cherished Gold Medal Dinner evolves into the Gold Medal Gala - a premier black-tie event for the field of radiation oncology. Honoring the extraordinary lifetime achievements of our most distinguished leaders and introducing the inaugural Corporate Partnership Award, the Gala is an opportunity to celebrate our past while actively funding our future.
Ticket sales are now closed.
This event is in-person only and will not be livestreamed or available onDemand.read more · Original Link ↗
Please note: The abstracts listed below will not be presented by the authors during this session. Instead, a designated discussant will highlight and discuss key findings and takeaways from these abstracts. · Original Link ↗
Leah Katz, MDModerator - Leah Katz
☆
Wed Sep 30 · 8:00 AM - 8:30 AM
SH 02 - Central Nervous System - Science Highlights
● Science Highlights
📍 Room 259
Please note: The abstracts listed below will not be presented by the authors during this session. Instead, a designated discussant will highlight and discuss key findings and takeaways from these abstracts. · Original Link ↗
Jennifer Yu, MD, PhDModerator - Cleveland Clinic
☆
Wed Sep 30 · 8:00 AM - 8:30 AM
SH 03 - Digital Health Innovation and Informatics - Science Highlights
● Science Highlights
📍 Room 257
Please note: The abstracts listed below will not be presented by the authors during this session. Instead, a designated discussant will highlight and discuss key findings and takeaways from these abstracts. · Original Link ↗
Hina Saeed, MDModerator - Baptist Health South Florida
Ying Xiao, PhD, FASTROModerator - University of Pennsylvania
☆
Wed Sep 30 · 8:00 AM - 8:30 AM
SH 04 - Gastrointestinal Cancer- Science Highlights
● Science Highlights
📍 Room 254
Please note: The abstracts listed below will not be presented by the authors during this session. Instead, a designated discussant will highlight and discuss key findings and takeaways from these abstracts. · Original Link ↗
Jennifer Wo, MD, FASTROModerator - Massachusetts General Hospital/ Harvard Medical School
☆
Wed Sep 30 · 8:00 AM - 8:30 AM
SH 05 - Genitourinary Cancer - Science Highlights
● Science Highlights
📍 Room 109
Please note: The abstracts listed below will not be presented by the authors during this session. Instead, a designated discussant will highlight and discuss key findings and takeaways from these abstracts. · Original Link ↗
Leslie Ballas, MD, FASTROModerator - Cedars Sinai
Stanley Liauw, MD, FASTROModerator - University of Chicago
☆
Wed Sep 30 · 8:00 AM - 9:00 AM
EDU 58 - Auto-Planning in the Wild: Lessons Learned from Clinical Deployment
● Education
📍 Room 153
Automated treatment planning has long promised more consistent plan quality and faster turnaround from simulation to treatment, yet published guidance on real-world clinical deployment remains limited.Automated treatment planning has long promised more consistent plan quality and faster turnaround from simulation to treatment, yet published guidance on real-world clinical deployment remains limited. This session brings "Auto-planning in the Wild" to the ASTRO community through practical lessons learned from early adopters implementing automated planning across diverse environments (i.e., single hospitals, multi-satellite health systems, and networked planning models). Speakers representing both clinicians and medical physics will share implementation stories that move beyond controlled benchmarks to day-to-day operations, including required infrastructure, workflow redesign, staffing considerations, QA and governance approaches, and strategies for maintaining clinical safety and consistency at scale. Attendees will learn common barriers and pitfalls (technical integration, change management, edge cases and acceptance criteria) alongside pragmatic solutions that have enabled sustainable deployment. Emphasis will be placed on translating operational data (plan quality uniformity, efficiency gains and reliability) into clear dialogue that communicates radiotherapy's value to clinical teams and institutional stakeholders, supporting broader adoption and advancing patient care.
Learning Objectives:
- Describe the infrastructure, governance and workflow redesign required to deploy automated treatment planning safely in routine clinical practice.
- Assess auto-planning performance using practical plan quality and safety criteria (e.g., acceptance thresholds, QA checkpoints and monitoring metrics) to guide clinical adoption.
- Identify common barriers and failure modes in clinical deployment and determine mitigation strategies, including how to communicate operational results to stakeholders to support sustainable implementation.read more · Original Link ↗
Joseph Harms, PhDModerator - Washington University in St. Louis
☆
Wed Sep 30 · 8:00 AM - 9:00 AM
EDU 56 - Challenging Cases: The Evolving Role of Radiation Therapy for Rare Genitourinary Cancers
● Education
📍 Room 258
Rare genitourinary malignancies present significant diagnostic and therapeutic hurdles and cumulatively account for a considerable proportion of patients seen in radiation oncology.Rare genitourinary malignancies present significant diagnostic and therapeutic hurdles and cumulatively account for a considerable proportion of patients seen in radiation oncology. Management of rare GU malignancies requires a high degree of coordination between urologic surgeons, medical oncologists, radiation oncologists and pathologists. This session utilizes a case-based approach to explore the clinical decision making process for orphan GU tumors including penile cancer, urethral tumors, testicular cancer and adrenocortical carcinoma. These malignancies present significant diagnostic and therapeutic hurdles and emphasis will be placed on the importance of multi-specialty collaboration to improve outcomes. An expert multi-disciplinary panel will review the latest evidence-based interventions, discuss the role of molecular profiling in personalized care, and identify strategies for managing treatment-related toxicities in these complex patients.
Learning Objectives:
- Identify and differentiate the unique histopathological features and clinical presentations of rare GU malignancies (e.g., urethral cancer, testicular cancer, and penile squamous cell carcinoma).
- Evaluate current evidence-based strategies and expert consensus recommendations for the management of rare GU tumors, including where high-quality randomized controlled trial data are unavailable.
- Develop individualized treatment plans that integrate surgical, systemic and radiation therapies, specifically focusing on the utility of emerging biomarkers and the sequencing of novel agents like immunotherapy and targeted inhibitors.read more · Original Link ↗
Omar Mian, MD, PhDModerator - Fred Hutchinson Research Center
☆
Wed Sep 30 · 8:00 AM - 9:00 AM
QP 35 - Digital Allies: AI Tools Built for the Real Clinical Environment
● Quick Pitch
📍 Room 160
Quick Pitch sessions provide opportunities for presenters to summarize outcomes while highlighting key takeaways from their research in a fast-paced format to present concise takeaways. · Original Link ↗
Sarah Hoffe, MDModerator - Moffitt Cancer Center
☆
Wed Sep 30 · 8:00 AM - 9:00 AM
QP 36 - From Brachy to Beams to Biologics: Innovations in Esophageal and Liver Cancer
● Quick Pitch
📍 Room 162
Quick Pitch sessions provide opportunities for presenters to summarize outcomes while highlighting key takeaways from their research in a fast-paced format to present concise takeaways. · Original Link ↗
Zain Siddiqui, MD, FRCPCModerator - Penn State Cancer Institute
Ann Raldow, MD, MPHModerator - UCLA David Geffen School of Medicine/UCLA Medical Center
☆
Wed Sep 30 · 8:00 AM - 9:00 AM
QP 37 - From Detection to Re-treatment: Managing Radiorecurrent Prostate Cancer
● Quick Pitch
📍 Room 253
Quick Pitch sessions provide opportunities for presenters to summarize outcomes while highlighting key takeaways from their research in a fast-paced format to present concise takeaways. · Original Link ↗
Tyler Robin, MD, PhDModerator - University of Colorado School of Medicine, Deptartment of Radiation Oncology
Steven Seyedin, MDModerator - University of California Irvine
☆
Wed Sep 30 · 8:00 AM - 9:00 AM
QP 39 - Imaging for Positioning and Motion Management
● Quick Pitch
📍 Room 107
Quick Pitch sessions provide opportunities for presenters to summarize outcomes while highlighting key takeaways from their research in a fast-paced format to present concise takeaways. · Original Link ↗
Anna Rodrigues, PhD, MSModerator - Duke University Medical Center
Nesrin Dogan, PhDModerator - University of Miami
☆
Wed Sep 30 · 8:00 AM - 9:00 AM
QP 38 - Lung Quick Pitch: Oligometastatic and Oligoprogressive NSCLC
● Quick Pitch
📍 Room 156
Quick Pitch sessions provide opportunities for presenters to summarize outcomes while highlighting key takeaways from their research in a fast-paced format to present concise takeaways. · Original Link ↗
David Qian, MD, PhDModerator - MD Anderson Cancer Center
Shahed Badiyan, MDModerator - University of Texas Southwestern Medical Center
☆
Wed Sep 30 · 8:00 AM - 9:00 AM
EDU 57 - The Biology of Radiopharmaceuticals (RPTs): Beyond the Physical Properties
● Education
📍 Room 157
Targeted radionuclide therapy, also known as radiopharmaceuticals (RPTs), has recently gained significant interest as a modality to deliver a targeted therapeutic radiation dose to all sites of disease.Targeted radionuclide therapy, also known as radiopharmaceuticals (RPTs), has recently gained significant interest as a modality to deliver a targeted therapeutic radiation dose to all sites of disease. Selection of the radionuclide, the linker and/or vector, and the target binding site is critical: each radionuclide exhibits distinct properties, the linker influences binding, retention, and distribution of the RPT in the tumor, and the target must be easily accessible, specific to the tumor cell, and highly expressed in ideally all tumor cells. With the increased availability and clinical trials using RPTs in the clinic, it is imperative to understand and predict the therapeutic efficacy and potential toxicities of RPT therapy, as well as its mechanisms of action and its pharmacologic effect when administered in combination with systemic drugs and/or external beam radiotherapy. There is limited data, however, on the different radiobiologic effects of alpha- and beta-emitting radionuclide types. Further, not only do RPTs have a direct tumoricidal effect, but their therapeutic efficacy also appears to be mediated by the tumor microenvironment and immune response. RPTs that target molecules involved in DNA damage repair, such as PARP1, has shown promise in enhancing DNA damage of tumor cells with the potential to enhance the efficacy of subsequent fractionated radiotherapy. This session will therefore explore the radiobiologic effects of RPTs via direct cell kill, modulation of the tumor microenvironment (TME) and immunologic response, and when administered with systemic drugs and/or fractionated external beam radiotherapy.
Learning Objectives:
- Describe the different radiobiologic effects of alpha- versus beta-emitting RPTs, and understand the utility and barriers of using each RPT.
- Define the different mechanisms that RPTs can target tumors - direct cell kill, modulation of the tumor microenvironment (TME), and immunologic effects.
- Identify ways to enhance the efficacy of RPTs, including the delivery with fractionated external beam radiotherapy (EBRT) and with systemic therapies.read more · Original Link ↗
Craig Grossman, MD, PhD, MSModerator - University of Pittsburgh, UPMC Hillman Cancer Center
Built for you by(617)-PATRICK, Champion AI speaker
QP 41 - Biologic Determinants of Radiation Response
● Quick Pitch
📍 Room 157
Quick Pitch sessions provide opportunities for presenters to summarize outcomes while highlighting key takeaways from their research in a fast-paced format to present concise takeaways. · Original Link ↗
Kent Mouw, MD, PhDModerator - Dana-Farber Cancer Institute
David Yu, MD, PhD, FASTROModerator - Emory University
☆
Wed Sep 30 · 9:15 AM - 10:15 AM
QP 42 - Imaging-Derived Outcome Prediction
● Quick Pitch
📍 Room 153
Quick Pitch sessions provide opportunities for presenters to summarize outcomes while highlighting key takeaways from their research in a fast-paced format to present concise takeaways. · Original Link ↗
Lydia Wilson, PhD, MSModerator - Thomas Jefferson University
Stefan Both, PhDModerator - University Medical Center Groningen
☆
Wed Sep 30 · 9:15 AM - 10:15 AM
QP 40 - Personalized Therapy and Special Populations in Head and Neck Cancer
● Quick Pitch
📍 Room 156
Quick Pitch sessions provide opportunities for presenters to summarize outcomes while highlighting key takeaways from their research in a fast-paced format to present concise takeaways. · Original Link ↗
Lachlan McDowell, PhD, MBBS, FRANZCRModerator - Princess Alexandra Hospital
Ryan Morse, MDModerator - University of Kansas Medical Center
☆
Wed Sep 30 · 9:15 AM - 10:30 AM
SS 48 - Beyond Tumor Control: Quality of Life and Toxicity in Prostate RT
Adam Olson, MD, MSModerator - UPMC Hillman Cancer Center
Jay Shiao, MD, MS, MPHModerator - University of Kansas Cancer Center
☆
Wed Sep 30 · 9:15 AM - 10:30 AM
QP 47 - Research Highlights From Around the Globe
● Quick Pitch
📍 Room 254
Quick Pitch sessions provide opportunities for presenters to summarize outcomes while highlighting key takeaways from their research in a fast-paced format to present concise takeaways. · Original Link ↗
Gustavo Sarria, MDModerator - University Hospital Bonn
Vedang Murthy, MDModerator - Tata Memorial Centre
☆
Wed Sep 30 · 9:15 AM - 10:30 AM
SS 46 - Right-Sizing Radiation in Early Breast Cancer: Omission, Shortening, and Targeted Approaches
Kristin Redmond, MD, MPH, FASTROModerator - Johns Hopkins University
Donna Edwards, MD, PhDModerator - University of Michigan
☆
Wed Sep 30 · 9:15 AM - 9:45 AM
SH 06 - Gynecological Cancer - Science Highlights
● Science Highlights
📍 Room 256
Please note: The abstracts listed below will not be presented by the authors during this session. Instead, a designated discussant will highlight and discuss key findings and takeaways from these abstracts. · Original Link ↗
☆
Wed Sep 30 · 9:15 AM - 9:45 AM
SH 08 - Hematologic Malignancies - Science Highlights
● Science Highlights
📍 Room 109
Please note: The abstracts listed below will not be presented by the authors during this session. Instead, a designated discussant will highlight and discuss key findings and takeaways from these abstracts. · Original Link ↗
Jillian Gunther, MD, PhDModerator - The University of Texas MD Anderson Cancer Center
Bradford Hoppe, MD, MPH, FASTROModerator - Mayo Clinic Florida
☆
Wed Sep 30 · 9:15 AM - 9:45 AM
SH 09 - Lung Cancer/Thoracic Malignancies - Science Highlights
● Science Highlights
📍 Room 162
Please note: The abstracts listed below will not be presented by the authors during this session. Instead, a designated discussant will highlight and discuss key findings and takeaways from these abstracts. · Original Link ↗
Charles Simone, MD, FASTROModerator - New York Proton Center and Memorial Sloan Kettering Cancer Center
Jeffrey Bradley, MD, FASTROModerator - University of Pennsylvania
Built for you by(617)-PATRICK, Champion AI speaker
Please note: The abstracts listed below will not be presented by the authors during this session. Instead, a designated discussant will highlight and discuss key findings and takeaways from these abstracts. · Original Link ↗
Michelle Mierzwa, MDModerator - University of Michigan
☆
Wed Sep 30 · 10:45 AM - 11:15 AM
SH 11 - Pediatric Cancer - Science Highlights
● Science Highlights
📍 Room 109
Please note: The abstracts listed below will not be presented by the authors during this session. Instead, a designated discussant will highlight and discuss key findings and takeaways from these abstracts. · Original Link ↗
Daniel Indelicato, MD, FRCR, FASTROModerator - University of Florida Department of Radiation Oncology
☆
Wed Sep 30 · 10:45 AM - 11:15 AM
SH 12 - Sarcoma and Cutaneous Tumors - Science Highlights
● Science Highlights
📍 Room 157
Please note: The abstracts listed below will not be presented by the authors during this session. Instead, a designated discussant will highlight and discuss key findings and takeaways from these abstracts. · Original Link ↗
Andrew Bishop, MDModerator - UT MD Anderson Cancer Center
☆
Wed Sep 30 · 10:45 AM - 11:45 AM
QP 45 - AI Powered Dose Prediction and Segmentation
● Quick Pitch
📍 Room 153
Quick Pitch sessions provide opportunities for presenters to summarize outcomes while highlighting key takeaways from their research in a fast-paced format to present concise takeaways. · Original Link ↗
Lei Ren, PhDModerator - University of Maryland Cancer Center
Joel St-Aubin, PhDModerator - University of Iowa
☆
Wed Sep 30 · 10:45 AM - 11:45 AM
QP 44 - Biology and Prevention of Radiation-Induced Injury
● Quick Pitch
📍 Room 156
Quick Pitch sessions provide opportunities for presenters to summarize outcomes while highlighting key takeaways from their research in a fast-paced format to present concise takeaways. · Original Link ↗
Yvonne Mowery, MD, PhD, BSModerator - University of Pittsburgh Medical Center
Carmen Bergom, MD, PhD, FASTROModerator - Washington University School of Medicine
☆
Wed Sep 30 · 10:45 AM - 11:45 AM
QP 46 - Imaging for Planning
● Quick Pitch
📍 Room 160
Quick Pitch sessions provide opportunities for presenters to summarize outcomes while highlighting key takeaways from their research in a fast-paced format to present concise takeaways. · Original Link ↗
Amit Sawant, PhDModerator - University of Maryland
Jessica Miller, PhDModerator - University of Wisconsin Madison
☆
Wed Sep 30 · 10:45 AM - 11:45 AM
QP 43 - Treatment Strategies in Localized and Advanced Prostate Cancer
● Quick Pitch
📍 Room 107
Quick Pitch sessions provide opportunities for presenters to summarize outcomes while highlighting key takeaways from their research in a fast-paced format to present concise takeaways. · Original Link ↗
Mark Hurwitz, MD, FASTROModerator - New York Medical College/Westchester Medical Center Health
Martin King, MD, PhDModerator - Brigham and Women's Hospital
Built for you by(617)-PATRICK, Champion AI speaker
Let AI help you determine which sessions to attend 🤖
The steps below are for copying all the session descriptions and putting them into your own AI model - Claude, Gemini, ChatGPT, Co-Pilot and so on. This is the best way to do it on your laptop or PC. If you don't have your laptop with you, use the phone feature in red at the top of this page.
Tip: This is a large session list. Claude (claude.ai) handles the full file reliably - if you don't have a window open, start one there. Other tools like ChatGPT and Gemini may silently cut off the data - the verification step in the prompt will catch that.
Paste one of these two prompts. The short one is enough; the longer one gives the AI a role, context about the data, and a clear task.
Pick the 10 best sessions for me and say why.
ROLE: Expert conference advisor for ASTRO 2026 attendees CONTEXT: I'm pasting over 100 sessions for the ASTRO 2026.
I'm a radiation oncologist. I want practical clinical sessions on breast, prostate and lung cancer treatment, how AI is being used in imaging and outcome prediction, and time to connect with colleagues and residents. GOAL: Pick the top 10 sessions for me. OUTPUT FORMAT: List in chronological order. Do NOT number them sequentially.
Instead, start each entry with its relevance rank in bold, like: Rank #3 of over 100 - Session Title.
Follow with the day and time, then 2-3 sentences on why it fits my goals. VERIFICATION: Before answering, confirm how many sessions you received.
You should have at least 100. If you received significantly fewer,
tell me immediately - my paste was probably truncated.
How cool am I? 😎
Which sessions are right for you?
Describe yourself and what you want from ASTRO 2026. The more specific you are, the better this works.
You can also say how many you want or when you're free - “just my top 3”, “give me 20”, “only Friday afternoon”. You get 5 unless you ask for more.
There is a daily limit on the phone version
so it can stay free for everyone at the event.
However, you can run it as many times as you want using your own AI account at home:
go to the bottom of the page
tap Copy this longer prompt
paste it into Claude, ChatGPT, or Gemini.
Powered by Claude. Your text is sent to Anthropic to generate the ranking, and is logged on this site so the feature can be improved. Please don't type anything confidential.
